• InSilc Plenary Meeting – Pisa

    The next InSilc plenary meeting will be held in CNR – National Research Council based in Pisa, Italy on 12th/13th March. The plenary meeting will take place almost one year and half into

    Read more »
  • InSilc Plenary Meeting – Rotterdam

      The latest InSilc plenary meeting was held in Erasmus University Medical Center based in Rotterdam, Netherlands on 29th/30th November. ERASMUS MC is affiliated with Erasmus University and home to

    Read more »
  • Funding

    The project has received funding from the European Union’s Horizon 2020 research and innovation programme

    Read more »
  • The InSilc Project

    The aim of InSilc: In-silico trials for drug-eluting BVS development and evaluation is to develop an in-silicoclinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS),

    Read more »
  • Who are we?

    This is the excerpt for a featured post.

    Read more »

Home

The aim of InSilc: In-silico trials for drug-eluting BVS development and evaluation is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), through building on the comprehensive biological and biomedical knowledge and advanced modelling approaches, towards simulating their implantation performance in the individual cardiovascular physiology.

The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for mechanical behaviour, deployment and degradation, fluid dynamics, in the micro– and macroscale, and myocardial perfusion for predicting the drug-eluting BVS and vascular wall interaction, in the short– and medium/long term.

New-fig